In 2020 the industry saw a surge in the adoption of decentralized clinical trials. The model allowed drug developers to continue their studies while keeping patients safe and out of clinics. As the COVID-19 pandemic winds down, most researchers expect the decentralized model to be the new norm going forward. Still, there are challenges that will need to be overcome for this new model to succeed. A research report published by Oracle Health Sciences has identified several of those challenges that still exist.
In this webinar segment, Tero Laulajainen, VP and head of global clinical science and operations for UCB, and Hassan Kadhim, global head of clinical trial business capabilities, clinical innovation, and industry collaborations at Bristol-Myers Squibb discuss decentralized trials, new technologies, and integration issues that can arise when converting studies to a virtual model.